NCT04480697View on ClinicalTrials.gov

Study of Safety, Tolerability and PK, PD of HPG1860 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

September 23, 2019

Primary Completion Date

November 25, 2020

Study Completion Date

August 7, 2021

Conditions
Healthy
Interventions
DRUG

HPG1860

6 subjects randomized to active compound and 2 subjects randomized to placebo

Trial Locations (1)

21201

Pharmaron CPC InC, Baltimore

All Listed Sponsors
lead

Hepagene (Shanghai) Co., Ltd.

INDUSTRY

NCT04480697 - Study of Safety, Tolerability and PK, PD of HPG1860 in Healthy Subjects | Biotech Hunter | Biotech Hunter